A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder

Current Medical Research and Opinion

Volumn 23, Issue 7, 2007, Pages 1605-1614

  Wade, Alan G ^a,c   Gembert, K ^b   Florea, I ^b  

^a CPS Clinical Research Centre   (United Kingdom)

^b H LUNDBECK A S   (Denmark)

^c CPS Research   (United Kingdom)

Author keywords

Depression; Duloxetine; Escitalopram; Long term; MADRS; Tolerability

Indexed keywords

DULOXETINE; ESCITALOPRAM;

ADULT; AGED; AGITATION; ANALYSIS OF VARIANCE; ANXIETY; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERHIDROSIS; INFLUENZA; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; VOMITING; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; THIOPHENES;

EID: 34347241658     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X210732     Document Type: Article

References (25)

1. Bostwick JM, Pankratz VS. Affective disorders and suicide risk: a reexamination. Am J Psychiatry 2000;157:1925-32
2. Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002;180:396-404
3. Sanchez C, Bøgesø KP, Ebert B, et al. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology 2004;174:163-76
4. Bielski RJ, Ventura D, Chang C-C. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004;65:1190-6
5. Montgomery SA, Andersen HF. Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 2006;21:297-309
6. Montgomery S A, Huusom AKT, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004;50:57-64
7. Nierenberg A, Greist J, Mallickrodt C, et al. Onset of antidepressant action and acute efficacy and safety of duloxetine versus escitalopram and placebo in the treatment of major depressive disorder. Neuropsychopharmacology 2005;30(Suppl 1):S142
8. Jonas J, Bose A, Alexopoulos GS, et al. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Neuropsychopharmacology 2006;31:S166
9. Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002;3:5-43
10. NICE Clinical Guideline 23 (amended). Depression: management of depression in primary and secondary care (issue date April, 2006). http://guidance.nice.org.uk/CG23/niceguidance/pdf/English/download.dspx. Last accessed 2 May, 2007
11. ICH. (1996) ICH Harmonised Tripartite Guideline E6: Guideline for Good Clinical Practice. Available from: http://www.emea.eu.int/pdfs/human/ich/ 013595en.pdf#search= %22ich%20e6%22. Last accessed 29 March, 2007
12. World Medical Association (WMA). (1964) Declaration of Helsinki: Ethical principles for medical research involving human subjects. Available from: http://www.wma.net/e/ethicsunit/helsinki.htm. Last accessed 29 March, 2007
13. Lecrubier Y, Sheehan DV, Weiller E, et al. The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry 1997;12:224-31
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text Revision (DSM-IV-TR). American Psychiatric Publishing Inc. USA, 1994
15. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
16. Guy W. ECDEU Assessment Manual for Psychopharmacology (rev., 1976) Biometric Laboratory. The George Washington University, Kensington, Maryland. US Dept. of Health, Education, and Welfare - DHEW Publication No. (ADM) 218-22
17. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
18. Hamilton M. The assessment of anxiety states by rating. Br Med Psychol 1959;32:50-5
19. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996;11(Suppl 3):89-95
20. Ware JE, Snow KK, Kosinski M, et al. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center, 1993
21. Maier W, Philipp M. Improving the assessment of severity of depressive states: a reduction of the Hamilton Depression Scale. Pharmacopsychiatry 1985;18:114-15
22. Belzer K, Schneier FR. Comorbidity of anxiety and depressive disorders: issues in conceptualization, assessment, and treatment. J Psychiatr Pract 2004;10:296-306
23. Boulenger JP, Huusom AKT, Horea I, et al. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 2006;22:1331-41
24. Olie JP, Tonnoir B, Menard F, et al. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety. Depress Anxiety 2007;doi:10.1002/da.20207
25. Bech P, Kajdasz DK, Porsdal V. Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder. Psychopharmacology 2006;188: 273-80